Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27753198 | 0.82 | KMT2A (0.44) | MAPTHSD17B10ALDH1A1GFERKMT2A | |
| SCHEMBL108390 | 0.81 | MAPT (0.50) | MAPTHSD17B10ALDH1A1KMT2ANPSR1 | |
| SCHEMBL162705 | 0.80 | ALDH1A1 (0.42) | MAPTHSD17B10ALDH1A1KMT2ANPSR1 | |
| SCHEMBL27858618 | 0.79 | HSD17B10 (0.48) | MAPTHSD17B10ALDH1A1GFERKMT2A | |
| SCHEMBL129264 | 0.78 | ALDH1A1 (0.41) | MAPTHSD17B10ALDH1A1KMT2ANPSR1 | |
| SCHEMBL27666715 | 0.78 | ALDH1A1 (0.41) | MAPTHSD17B10ALDH1A1KMT2ANPSR1 | |
| SCHEMBL15319329 | 0.78 | ALDH1A1 (0.41) | MAPTHSD17B10ALDH1A1KMT2ANPSR1 | |
| SCHEMBL1682676 | 0.78 | GRM5 (0.48) | MAPTHSD17B10ALDH1A1KMT2ANPSR1 | |
| SCHEMBL15174136 | 0.78 | HSD17B10 (0.39) | MAPTHSD17B10ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL17716404 | 0.77 | L3MBTL1 (0.50) | MAPTALDH1A1KMT2AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118765280-A | RIP1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023079294-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-05-11 | — | — | WO | disclosed |
| EP-3564239-B9 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3668512-B1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3668513-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20110245268-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-6444666-B1 | SUCH AS ALZHEIMER'S DISEASE; SUBSTITUTED 1,2,4-TRIAZOLO(4,3-B) PYRIDAZINE DERIVATIVES ARE LIGANDS FOR GABA RECEPTORS; CONVULSANT ACTIVITY IS REDUCED OR ELIMINATED | MERCK SHARP & DOHME LTD. (GB) | 2002-09-03 | — | — | US | disclosed |
| US-6297235-B1 | ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2001-10-02 | — | — | US | disclosed |
| EP-1107967-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LTD. (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012505-A2 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR TREATING ANXIETY AND ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245268-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | MAPT 2956/4885HSD17B10 2365/4885ALDH1A1 1175/4885 |
| US-11590132-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | MAPT 3891/4885HSD17B10 1064/4885ALDH1A1 322/4885 |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | MAPT 2956/4885HSD17B10 2365/4885ALDH1A1 1175/4885 |
| US-20210077490-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | MAPT 3891/4885HSD17B10 1064/4885ALDH1A1 322/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | MAPT 4877/4885HSD17B10 76/4885ALDH1A1 580/4885 |
| US-11040036-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | MAPT 3891/4885HSD17B10 1064/4885ALDH1A1 322/4885 |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | MAPT 2956/4885HSD17B10 2365/4885ALDH1A1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.